yttrium radioisotopes has been researched along with Carcinoid Tumor in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| August, C; Maker, AV; Maker, VK; Weisenberg, E | 1 |
| Ardill, JE; Eatock, M; Johnston, BT; McCance, DR | 1 |
| Eriksson, B; Garske, U; Granberg, D; Kindmark, H; Nyman, R; Oberg, K; Welin, S | 1 |
| Campana, D; Capurso, G; Delle Fave, G; Merola, E; Monarca, B; Panzuto, F; Tomassetti, P | 1 |
| Anthony, L; Baulieu, JL; Benson, AB; Borson-Chazot, F; Bouterfa, H; Bushnell, DL; Connolly, M; Grossman, AB; Hicks, RJ; Kacena, KA; LaFrance, N; Li, Y; Menda, Y; O'Dorisio, MS; O'Dorisio, TM; Oberg, K; Pauwels, SA; Van Cutsem, E | 1 |
| Reidy-Lagunes, D; Thornton, R | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Bartolomei, M; Bodei, L; Davì, MV; Falconi, M; Ferdeghini, M; Francia, G; Lo Cascio, V; Oliani, C; Paganelli, G; Reghellin, D; Scilanga, L | 1 |
| Angelberger, P; Bischof, C; Gludovacz, D; Hamilton, G; Kaserer, K; Kofler, A; Leimer, M; Pangerl, T; Peck-Radosavljevic, M; Schlangbauer-Wadl, H; Smith-Jones, PM; Traub, T; Virgolini, I | 1 |
| Bartenstein, PR; Brockmann, JJ; Buchholz, HG; Engelbach, MJ; Förster, GJ; Herzog, HR; Mäcke, HR; Reber, HJ; Rösch, FR | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C | 1 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
1 review(s) available for yttrium radioisotopes and Carcinoid Tumor
| Article | Year |
|---|---|
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
2 trial(s) available for yttrium radioisotopes and Carcinoid Tumor
| Article | Year |
|---|---|
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoid Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Octreotide; Yttrium Radioisotopes | 2010 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
10 other study(ies) available for yttrium radioisotopes and Carcinoid Tumor
| Article | Year |
|---|---|
Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis.
Topics: Carcinoid Tumor; Embolization, Therapeutic; Female; Hepatectomy; Hepatic Artery; Humans; Ileal Neoplasms; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Yttrium Radioisotopes | 2016 |
Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.
Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoid Tumor; Disease Progression; Drug Monitoring; Female; Humans; Interferon-alpha; Intestinal Neoplasms; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Neurokinin A; Somatostatin; Yttrium Radioisotopes | 2017 |
Selective internal radiation therapy in patients with carcinoid liver metastases.
Topics: Brachytherapy; Carcinoid Tumor; Chemoembolization, Therapeutic; Female; Gastrointestinal Neoplasms; Glass; Hepatic Artery; Humans; Liver Neoplasms; Microspheres; Resins, Synthetic; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid.
Topics: Aged; Carcinoid Tumor; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Ileal Neoplasms; Male; Octreotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Peptide; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2010 |
90Y-DOTATOC and nephrotoxicity.
Topics: Animals; Carcinoid Tumor; Humans; Intestinal Neoplasms; Kidney; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
Topics: Aged; Bone Neoplasms; Bronchial Neoplasms; Carcinoid Tumor; Humans; Liver Neoplasms; Male; Malignant Carcinoid Syndrome; Octreotide; Yttrium Radioisotopes | 2006 |
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoid Tumor; Cell Membrane; Colonic Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Thyroid Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 1999 |
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Topics: Aged; Carcinoid Tumor; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Radiation Dosage; Radiometry; Radiopharmaceuticals; Somatostatin; Tissue Distribution; Tomography, Emission-Computed; Yttrium Radioisotopes | 2001 |
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Topics: Carcinoid Tumor; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pain, Intractable; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2002 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |